abstract |
(I) the immunomodulatory agent is selected from one or more of an activator of a co-stimulatory molecule or an inhibitor of an immune checkpoint molecule, and (ii) the immunomodulatory agent is selected from one or more of: A second therapeutic agent is LDK378, wherein a method of treating cancer in a subject is disclosed. |